Business Consultant

Thyroid eye disease market: New therapies enter the TED market

Articles, Business Consultant, Pharma Consultant

The newly approved drug teprotumumab can offer hope to adults with thyroid eye disease, a rare and potentially blinding condition....

Read More

Tepezza receives approval; a new way to treat Alzheimer’s; and a new anti-obesity molecule

Business Consultant, Pharma Consultant, Pharma news

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye...

Read More

Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102

Business Consultant, News, Pharma Consultant

The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for...

Read More

In a blind race to cure HIV, can Gene therapy be a deal-breaker?

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant

HIV infection has become a global health burden, has claimed over 32 million lives so far since the very first case of AIDS was reported in...

Read More

Thumbs down to NKTR-181, Lilly expands its insulin armamentarium, 23andMe out-licences its drug

Business Consultant, Pharma Consultant, Pharma news

The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain.  The FDA’s...

Read More

Malignant Pleural Mesothelioma Upcoming Therapies

Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, DelveInsight's Oncology based Reports, Pharma Consultant, Snippets

Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and...

Read More
Close